Welcome to our dedicated page for Artelo Biosciences SEC filings (Ticker: ARTL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Artelo Biosciences, Inc. (NASDAQ: ARTL) SEC filings page on Stock Titan provides structured access to the company’s U.S. Securities and Exchange Commission disclosures, with AI-powered tools to help interpret complex documents. As a clinical-stage biopharmaceutical company focused on lipid-signaling pathways and the endocannabinoid system, Artelo uses its SEC filings to report on clinical development, capital formation, governance changes, and listing status.
Here you can review Form 10-K annual reports and Form 10-Q quarterly reports (when filed) for detailed discussions of Artelo’s pipeline, including programs such as ART27.13 for cancer anorexia-cachexia syndrome, ART26.12 as a FABP5 inhibitor for chemotherapy-induced peripheral neuropathy, and ART12.11, its CBD-TMP cocrystal composition. These reports typically describe risk factors, research and development priorities, intellectual property, and liquidity and capital resources.
Form 8-K current reports are particularly important for ARTL, as they capture material events such as underwritten public offerings, private placements of convertible notes and warrants, cooperation agreements with shareholders, amendments to bylaws and articles of incorporation, executive appointments, and Nasdaq listing notifications. For example, an 8-K dated November 25, 2025 discloses a Nasdaq delist determination letter related to stockholders’ equity requirements and the company’s intention to appeal.
Investors can also use this page to access registration statements such as Form S-1 and Form S-3, which describe the terms of securities offerings, resale registrations for warrants and convertible notes, and related risk disclosures. Where available, Section 16 filings (Forms 3, 4, and 5) provide insight into insider ownership and transactions involving directors and officers.
Stock Titan’s platform enhances these filings with AI-generated summaries that highlight key terms, financial and capital structure changes, and program-related disclosures, helping users quickly understand how each document relates to Artelo’s clinical pipeline, governance, and Nasdaq listing status.
Artelo Biosciences reported a Form 4 insider transaction for President, CEO, CFO, Treasurer and Secretary Gregory D. Gorgas. He was granted 154,713 stock options on January 29, 2026 with an exercise price of $1.68 per share and expiration on January 29, 2036.
These options vest in equal monthly installments, with 1/48 of the shares vesting each month starting from a vesting commencement date of January 1, 2026, so long as he continues as a service provider. The entire grant is scheduled to be fully vested after four years.
Artelo Biosciences, Inc. reconvened its Annual Meeting of Stockholders on January 30, 2026 and reported the voting results. The meeting had previously been convened on December 31, 2025 and adjourned because there were not enough shares represented to form a quorum.
Of the 2,018,746 shares of common stock outstanding as of the December 10, 2025 record date, 1,017,816 shares were represented at the reconvened meeting, or approximately 50.4% of the shares entitled to vote. Stockholders cast votes on the election of two director nominees and on two additional matters, with detailed tallies provided for each item.
Artelo Biosciences, Inc. received a Nasdaq notice on January 14, 2026 stating it is not in compliance with Nasdaq Listing Rule 5620(a, the annual meeting rule, because its 2025 annual meeting was convened on December 31, 2025 but adjourned for lack of quorum and is scheduled to reconvene on January 30, 2026. Nasdaq indicated this annual meeting deficiency could serve as an additional basis for delisting.
The company has already presented to a Nasdaq Hearing Panel a plan to regain and maintain compliance with the previously disclosed deficiency in the
Artelo Biosciences, Inc. reported that Nasdaq has issued a determination to delist its common stock after the company failed to regain compliance with Nasdaq Listing Rule 5550(b)(1), which requires stockholders’ equity of at least $2,500,000. Artelo had submitted plans to Nasdaq on July 7, 2025 and August 29, 2025 that relied on raising additional capital, but the expected capital raise has not been completed.
On November 19, 2025, Nasdaq staff notified Artelo that, unless the company requests a hearing by November 26, 2025, its securities will be delisted on December 1, 2025. Artelo intends to appeal this determination to a Nasdaq hearing panel under the Listing Rule 5800 Series, which would stay further delisting actions during the appeal or any extension. The company’s common stock is expected to continue trading on Nasdaq under the symbol ARTL while the appeal process is pending.
Artelo Biosciences, Inc. (ARTL) reported the equity holdings of its Chief Financial Officer in a beneficial ownership statement. The filing lists two stock options to buy common stock, each with an exercise price of $11.03 per share. One option covers 5,000 shares of common stock and vests in equal monthly installments over four years starting from a vesting commencement date of January 1, 2025. The other option covers 2,500 shares of common stock, with half vesting on January 1, 2026 and the remaining half vesting on January 1, 2027, in each case contingent on continued service.
Artelo Biosciences, Inc. is registering up to 899,972 shares of common stock for resale by existing securityholders. These shares consist of 215,292 shares issuable upon conversion of convertible notes, 246,498 shares issuable upon exercise of warrants with a $6.24 exercise price, and 438,182 shares issuable upon exercise of warrants with a $3.40 exercise price. Artelo will not receive proceeds from the resale of these shares, but could receive approximately
The company highlights significant risks, including substantial doubt about its ability to continue as a going concern, driven by cash of about
Artelo Biosciences (ARTL) filed its Q3 2025 10‑Q, highlighting liquidity pressure and continued R&D spend. The company reported a net loss of $8.7 million for the nine months ended September 30, 2025, driven by operating expenses of $8.6 million. Cash and cash equivalents were $1.7 million as of September 30, 2025, and management disclosed substantial doubt about the company’s ability to continue as a going concern without additional financing.
To fund operations, Artelo executed multiple capital raises: $0.9 million in unsecured convertible notes on May 1; a June private placement with $1.4 million gross proceeds; an at‑the‑market program that sold 50,858 shares for $442,000 net in Q3; and a September underwritten offering with ~$3.0 million gross ($2.87 million net). Subsequent events include an October 1 underwritten offering of ~$2.0 million gross and an October 28 note/warrant financing of $690,000 in notes plus 438,182 warrants at $3.40. Shares outstanding were 2,018,746 as of November 10, 2025. The company also held $325,000 fair value of SOL digital assets (cost $250,000), which flows through earnings under ASU 2023‑08.
Artelo Biosciences entered into a Subscription Agreement and completed a private financing on October 28, 2025, issuing convertible notes totaling $690,154.69 and warrants for 438,182 common shares at $3.40. Investors acquired these securities by converting amounts due at maturity under notes issued on May 1, 2025.
The notes carry 12% annual interest (increasing to 20% upon an Event of Default), mature six months after closing, and are convertible at $3.40 before maturity. The warrants are immediately exercisable for five years, with cash or cashless exercise if no effective resale registration is available, and include standard anti-dilution protections.
Artelo agreed to file a resale registration statement within 20 calendar days of closing and keep it effective until Rule 144 conditions are met. A 4.9% beneficial ownership cap applies, adjustable at a holder’s election up to 19.9%. Directors participated, including Connie Matsui $110,842.52 and 70,376 warrant shares, and Gregory Gorgas $27,710.36 and 17,592 warrant shares.
Artelo Biosciences (ARTL): Director insider transaction reported. On October 28, 2025, a portion of a convertible note issued on May 1, 2025 was automatically converted into a warrant to buy 38,346 shares of common stock at an exercise price of $6.24, expiring October 28, 2030.
On the same date, under a Subscription Agreement, the remaining portion of the May note held by the reporting person was converted and reinvested into (i) a new convertible note (the “October Note”) and (ii) a warrant to buy 70,376 shares at $3.40, expiring October 28, 2030. The filing indicates a principal amount of $110,843 for the October Note, which is convertible into common stock and lists dates of exercisability beginning October 28, 2025 and expiration on April 28, 2026.
Artelo Biosciences (ARTL) reported a director’s Form 4 detailing convertible note actions on 10/28/2025. A portion of a May 1, 2025 convertible note automatically converted into a warrant with a $6.24 exercise price. The remaining portion was converted and reinvested into a new October Note and a second warrant with a $3.40 exercise price.
The Form 4 lists two new warrants for 6,846 and 12,566 shares of common stock, each expiring on 10/28/2030. The October Note may be converted, at the holder’s election, into common stock at any time prior to repayment of principal and accrued interest.